Company intelligence / Profile preview
Phrixus Pharmaceuticals, Inc.
Ann Arbor, Michigan, United Statesphrixuspharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Phrixus Pharmaceuticals developed Carmeseal-MD (Poloxamer 188 NF or P-188 NF) for treating Duchenne muscular dystrophy. The company conducted a Phase 2 clinical trial of P-188 NF in non-ambulatory patients with DMD. The trial was designed as a single-center, open-label study to evaluate the safety, tolerability, and efficacy of daily subcutaneous dosing in non-ambulatory boys with DMD. The trial was terminated according to clinical trial records.
- Therapeutic areas
- Rare DiseasesCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Cincinnati Children's HospitalDMD patient organizations
Beyond the preview
Go deeper on Phrixus Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phrixus Pharmaceuticals, Inc..